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Abstract
GBV-B virus is a close relative to hepatitis C virus (HCV) that causes hepatitis in tamarins, and thus, is an attractive surrogate model
for HCV. In this study, we demonstrate that the host range of GBV-B extends to the common marmoset with an infection profile similar
to that observed for tamarins. Marmoset hepatocytes were susceptible to in vitro infection with GBV-B. Virus was efficiently secreted into
the medium, and approximately 25% of hepatocytes were positive for NS3 staining. In an attempt to induce persistent infections, tamarins
were immunosuppressed with FK506 and inoculated with GBV-B. Although no chronic infections were induced, the duration of viremia
was increased in most animals. In one animal, the duration of viremia was extended to 46 weeks, but viral clearance occurred 18 weeks after
stopping FK506 therapy. The greater availability of marmosets in comparison to tamarins will greatly facilitate future research efforts with
this model.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
GBV-B is the virus most closely related to hepatitis C
virus (HCV) based on phylogenetic analysis (Muerhoff et
al., 1995; Robertson et al., 1998; Ohba et al., 1996) and as
such GBV-B represents an important surrogate model for
HCV infections. The history of the GB agent is complex and
originates with the inoculation of tamarins with serum ob-
tained from a surgeon with the initials G.B. who contracted
hepatitis (for review, see Beames et al., 2001). In the 1960s,
Deinhardt inoculated tamarins with this serum and some of
the animals appeared to have contracted hepatitis from the
inoculation (Deinhardt et al., 1967). Although extensive
research on the agent was performed following these initial
studies, the technological limitations at the time prevented
the isolation and characterization of the agent. Nearly three
decades later, the nucleic acids from two viruses were
cloned from serum representing a serial passage of the
original tamarin serum (Simons et al., 1995b). The viruses
were designated GBV-A and GBV-B due to their relation-
ship to the original GB studies. A third related virus was
subsequently cloned from human serum and designated
GBV-C (Simons et al., 1995a) or hepatitis G virus (Linnen
et al., 1996). All three viruses are closely related to HCV
with GBV-B being the only hepatotropic member of the
group and the most closely related to HCV (Muerhoff et al.,
1995; Ohba et al., 1996).
Subsequent studies have suggested that GBV-B is of
New World primate origin and that it was isolated by
chance during the inoculation of human serum into tamarins
already infected with GBV-B. This assumption is based on
the fact that GBV-B has not been recovered from humans
and the fact that GBV-B has a very narrow host range for
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tamarins and other closely related New World monkeys
(this study and Bukh et al., 2001). The fact that it has not
been recovered a second time from tamarins may be due to
the rapid resolution of the acute infection in tamarins, the
low propensity of the virus to induce persistent infections,
and the limited number of wild-caught tamarins that have
been examined immediately upon introduction into captiv-
ity. In contrast, GBV-A is closely related to the human
GBV-C virus, and members of this family frequently cause
persistent infections and have been isolated from a number
of primates (Bukh and Apgar, 1997; Leary et al., 1996;
Birkenmeyer et al., 1998).
The GBV-B/tamarin model overcomes a number of lim-
itations encountered working with HCV (Beames et al.,
2001; Lanford and Bigger, 2002). GBV-B replicates to
levels several logs higher than what is observed in HCV-
infected humans and chimpanzees, thus making the detec-
tion of viral RNA and antigens more feasible. The tamarin
represents a less expensive, more readily available, and
smaller animal model than the chimpanzee. Although lim-
ited replication of HCV in vitro has been reported for a
number of systems, the tamarin primary hepatocyte system
is more suitable for virological studies (Beames et al.,
2000). This system has been used to examine the antiviral
activity of poly (IC) for GBV-B and to demonstrate the
induction of error-prone replication by ribavirin (Lanford et
al., 2001). Although the recently developed (Lohmann et
al., 1999) and improved (Lohmann et al., 2001; Blight et al.,
2000) HCV replicon system will greatly advance many
types of studies with HCV, it cannot replace the need for a
virus-based culture system and a small animal model.
HCV and GBV-B polyproteins possess approximately
25–30% homology at the amino acid level (Muerhoff et al.,
1995), while the 5 and 3 untranslated regions are more
distinct (Muerhoff et al., 1995; Bukh et al., 1999; Rijnbrand
et al., 2000). This high level of homology has lead to the
anticipation that antiviral compounds developed for HCV
will be active against GBV-B. This concept is supported by
the observation that the GBV-B NS3 protease correctly
processes the HCV polyprotein (Scarselli et al., 1997) and
that HCV/GBV-B chimeric NS3 proteins are enzymatically
active (Butkiewicz et al., 2000). Infectious cDNA clones of
GBV-B have been produced that induced hepatitis upon
intrahepatic inoculation of tamarins with in vitro transcribed
RNA (Bukh et al., 1999; A. Martin et al., in preparation).
The tamarin has been the preferred model for infections
with GBV-B and several species of Saguinus have been
shown to be susceptible to GBV-B, including oedipus, my-
stax, labiatus, and nigricollis (Beames et al., 2000; Lanford
et al., 2001; Schlauder et al., 1995; Bukh et al., 1999;
Deinhardt et al., 1967). Owl monkeys are also susceptible to
GBV-B infection, but the levels of viremia are several logs
lower than those observed in tamarins, making this animal
model less amenable for most studies (Bukh et al., 2001).
Although in the past many species of tamarins were bred for
biomedical research, few colonies remain today. Thus, al-
though tamarins are currently the preferred model for
GBV-B studies, they are limited in availability. In contrast,
common marmosets (Callithrix jaccus) are easier to manage
as breeding colonies and are currently bred for biomedical
research at a number of facilities. Although some confusion
exists in the literature, because some species of tamarins
were at one time referred to as marmosets, no previous
studies appear to have directly assessed the susceptibility of
the common marmoset for GBV-B infections, nor have they
been evaluated since the development of quantitative RT-
PCR for GBV-B RNA and immunological assays for anti-
body responses.
In this study, we demonstrate that marmosets are suscep-
tible to infection with GBV-B, and marmoset hepatocytes
are equivalent to tamarin hepatocytes as a culture system for
GBV-B. In addition, although immunosuppression extended
the duration of viremia in some animals, no chronic infec-
tions were observed in four immunosuppressed tamarins.
Results and discussion
Comparison of infection profiles for GBV-B in tamarins,
marmosets, and spider monkeys
To examine the susceptibility of the common marmoset for
GBV-B infections, two animals were inoculated with GBV-B
at 5.6 107 genome equivalents (GE) and were monitored for
viral RNA by quantitative RT-PCR assay (TaqMan), for anti-
body response to the NS3 protein by enzyme-linked immu-
nosorbent assay (ELISA), and for liver pathology by elevations
in the liver enzyme alanine transaminase (ALT) (Fig. 1). Both
animals exhibited high levels of viremia within 2 weeks posti-
noculation, the first time point examined. The level of viral
RNA in the serum of marmoset 17067 was 1.1  108 GE/ml
of serum by week 2. Viremia peaked on week 6 at 3.4  108
GE/ml of serum and began to decline by week 10. Viral
clearance was observed on week 16. An antibody response to
NS3 was first observed at week 8 and increased to peak values
by week 10, the time at which viremia began to decline. No
significant increase in ALT, AST, or GGT was observed at any
time. Marmoset 17089 had a lower level of viremia that peaked
on week 4 at 2.0  107 GE/ml and began to decline by week
8. Viremia was undetectable first at week 16, but was again
positive on week 18, and then negative thereafter. Similar to
17067, no increase in liver enzymes was detected, but in
contrast to 17067, no antibody response to NS3 was detected
by ELISA (Fig. 1). Although some differences were observed
in the infection profiles for the two marmosets, they were both
within the range we have observed in tamarin infections.
For comparison purposes, two tamarin profiles (oedipus,
12024 and 12026) are presented in Fig. 2. Both animals
exhibited increases in viremia to greater than 4  108
GE/ml of serum by week 2 postinoculation. Clearance of
viremia occurred by 16–18 weeks. Although increases in
ALT were observed in both animals by week 2 postinocu-
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lation, peak ALT levels were not observed until week 10–
12. The early rise in ALT could be due either to the innate
immune response to infected cells or possibly to some
cytopathic effect due to the high levels of GBV-B replica-
tion. The decline in viremia tended to occur after peak ALT.
This was especially evident in tamarin 12024. Both the lack
of an ALT rise in marmosets and the differences in the
kinetics of ALT rise and viremia decline in the tamarins
suggest that destruction of infected hepatocytes is not the
primary mechanism of viral clearance and that noncytolytic,
cytokine-mediated clearance of viral RNA is likely in-
volved. Although the limited data from these animals sug-
gest that some differences may exist between GBV-B in-
fections in marmosets and tamarins, we have observed
tamarins that do not have significant rises in ALT and lack
anti-NS3 responses, as well. The assays for antibodies to the
other viral antigens have not been developed. No response
to NS5B has been observed in any of the animals studied
thus far. All of the anti-GBV-B ELISA assays should be
considered preliminary at this point, and greater immuno-
logical responses may become apparent with improved as-
says.
To better appreciate the variation observed in viremia in
both marmosets and tamarins, the profiles of two marmosets
(dashed lines) and four tamarins (solid lines) were super-
imposed in Fig. 3. At this time, profiles from a sufficient
number of both marmosets and tamarins are not available to
conclude whether subtle differences exist in GBV-B infec-
tions between the two animal models. However, the data
demonstrate that GBV-B infections in marmosets are sim-
Fig. 2. Infection profile of GBV-B-infected tamarins. The GBV-B infection
profiles of tamarins 12024 and 12026 are depicted. Animals were inocu-
lated with tamarin serum containing 7.9  104 and 3.3  105 genome
equivalents of GBV-B RNA, respectively. Quantitative real-time RT-PCR
(TaqMan) assays were used to determine the levels of GBV-B RNA in the
serum, and values were expressed in genome equivalents (GE)/ml of serum
(shaded bars). Serum samples that were tested but were RT-PCR negative
are indicated by shaded triangles. Liver damage, as measured by serum
ALT levels (open circles), and seroconversion for antibody to the NS3
protein (anti-NS3 ELISA absorbance, triangles), are indicated by line
graphs. A portion of the data for animals 12024 and 12026 was previously
published (Beames et al., 2000) and is shown here for comparison to the
marmoset profiles shown in Fig. 1. Although similar infection profiles for
many tamarins are available from our previously unpublished studies (see
Fig. 3), most animals were experimentally manipulated in some manner,
and thus, were not considered directly comparable to the marmosets.
Fig. 1. Infection profile of GBV-B-infected marmosets. The GBV-B in-
fection profiles of marmosets 17067 and 17089 are depicted. Animals were
inoculated with tamarin serum containing 5.6  107 genome equivalents of
GBV-B RNA. Quantitative real-time RT-PCR (TaqMan) assays were used
to determine the levels of GBV-B RNA in the serum, and values were
expressed in genome equivalents (GE)/ml of serum (shaded bars). Serum
samples that were tested but were RT-PCR negative are indicated by
shaded triangles. Liver damage, as measured by serum ALT levels (open
circles), and seroconversion for antibody to the NS3 protein (Anti-NS3
ELISA absorbance, triangles), are indicated by line graphs.
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ilar to those observed in tamarins and that the marmoset will
be a useful animal model for future GBV-B studies.
In vitro infection of marmoset hepatoctyes with GBV-B
One of the major advantages of the use of the GBV-B
model as a surrogate for HCV studies is the availability of
a primary hepatocyte culture system for in vitro replication
and antiviral studies. To evaluate the use of marmoset hepa-
tocytes for in vitro studies, an in vitro growth curve was
conducted using marmoset hepatocytes. Cultures were in-
fected 3 days after plating. The cultures were washed two
times following infection to remove residual virus, and
cultures were harvested at various times over 72 h to ex-
amine GBV-B RNA levels in cell RNA and culture medium
(Fig. 4). Time 0 was immediately after inoculation and
represents the level of virus attached or internalized by the
cells or released from the cultures into the medium after the
washes. By 48 h postinoculation, peak levels of viral RNA
were observed in the cells (1.3  107 GE per culture) and
culture medium (2.6  105 GE per culture), and a 590-fold
increase in secreted viral RNA occurred from 8 to 48 h.
To determine the percentage of cells infected, immuno-
histochemical staining for GBV-B NS3 was performed on
marmoset hepatocytes 3 days postinfection. The staining
procedure utilized the Fast Red substrate for alkaline phos-
phatase, and the cells were counterstained with hematoxy-
lin. A vivid red staining was apparent in greater than 25% of
the cells (Fig. 5A). The Fast Red substrate can also be
detected by fluorescence microscopy (Fig. 5B). The detec-
tion of infected cells using this method represents a signif-
icant improvement over our previously described immuno-
fluorescence staining for NS3 (Beames et al., 2000).
These studies indicated that the marmoset cultures were
suitable for GBV-B in vitro replication studies. The culture
medium used in our studies was developed over 10 years
ago to support a variety of differentiated hepatocyte func-
tions over a long period of culture. The system has been
used successfully with human, chimpanzee, baboon, rhesus,
marmoset, and tamarin hepatocytes, in studies that involved
lipoprotein metabolism, metabolic functions, HBV, HDV,
HCV, and GBV-B (Beames et al., 2000, 2001; Jacob et al.,
1989; Lanford et al., 1989, 1994; Lanford and Estlack,
1998; Rainwater and Lanford, 1989; Stephensen et al.,
1991; Sureau et al., 1991; Tam et al., 1997; White et al.,
1993, 1994). One limitation of the system, besides the
dependence on the use of primary cultures, was the com-
plexity of the original serum-free medium supplemented
with hormones, growth factors, and nutrients. We examined
a simplified version of this medium in these studies (see
Materials and methods), but prior to adoption of the sim-
plified medium, we examined replication and secretion of
GBV-B in marmoset cultures maintained in the original
(medium A) and simplified (medium B) media. Cultures
were inoculated in triplicate with either tamarin or marmo-
set serum containing GBV-B and harvested 3 days postin-
oculation. The results indicate that both media support
GBV-B infection, replication, and secretion and that similar
infections were obtained using either tamarin and marmoset
serum (Fig. 6). Other serum-free media formulations may
be suitable for cultivation of marmoset hepatocytes for
GBV-B replication studies, especially since these studies
are short term in nature. We have continued the use of a
complex formulation (the simplified formula B shown
above), because this medium supports numerous hepatocyte
Fig. 4. Growth curve of GBV-B in primary marmoset hepatocytes. Hepa-
tocytes cultured in six-well dishes were inoculated with 5 l GBV-B
containing tamarin serum diluted into serum-free medium using an adsorp-
tion period of 1 h. Cultures were washed two times to remove unabsorbed
virus and were harvested in duplicate at various times over a 72-h period.
Time 0 is immediately after inoculation and represents the level of virus
attached or internalized by the cells or released from the cultures into the
medium after the washes. Cell-associated (closed circles) and secreted
(open circles) GBV-B RNA were quantified by TaqMan RT-PCR and
expressed as GE per culture.
Fig. 3. Comparison of viremia in GBV-B-infected marmosets and tamarins.
The line graphs depicting the levels of serum viral RNA during GBV-B
infections of two marmosets (dashed lines, data from Fig. 1) and four
tamarins (solid lines, data from Fig. 2 plus two other tamarins) are super-
imposed. In two animals, one marmoset and one tamarin, the RT-PCR
values declined to below the limit of detection and then returned to positive
values. The data suggest that GBV-B infections in marmosets and tamarins
are comparable.
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functions over long culture times in a number of different
species of primate hepatocyte cultures.
Effect of immunosuppression on GBV-B infections
Previous studies have suggested that experimental infec-
tions with GBV-B do not induce persistent infections. This
is supported by the failure to observe persistent infections in
wild-caught tamarins and marmosets. However, recent data
indicate that persistent infections are possible. A single
animal receiving an intrahepatic inoculation with infectious
GBV-B RNA developed a persistent infection (A. Martin et
al., in preparation). To some degree, this limits the utiliza-
tion of this model, since one would like to have persistently
infected animals for a variety of studies including studies on
pathogenesis and evaluation of antiviral strategies. Two
approaches for the induction of persistent infections include
induction of transient immunosuppression during infection
and infection of animals at birth prior to the maturation of
the immune system.
We have focused on the former approach. Partial success
was attained in inducing a viremia of longer duration with
GBV-B by transient immunosuppression with FK506. A
total of four tamarins (S. mystax) were infected with GBV-B
Fig. 6. Comparisons of in vitro infection of marmoset hepatocytes main-
tained in different serum-free media. Cultures were inoculated in triplicate
with either tamarin or marmoset serum containing GBV-B and were
harvested 3 days postinoculation. The levels of viral RNA in the cells and
culture medium were similar whether the hepatocytes were cultured in
Medium A (top) or Medium B (bottom), and whether cultures were inoc-
ulated with marmoset serum (left side) or tamarin serum (right side).
Medium A and Medium B represent our previously published serum-free
medium and the simplified version listed under Materials and methods,
respectively.
Fig. 5. Immunohistochemical staining for GBV-B NS3. Marmoset hepa-
tocytes were grown on glass coverslips and were harvested 3 days after
inoculation with GBV-B. Cells were fixed in acetone for 10 min, stained
for NS3 using a rabbit anti-NS3/GST serum, developed using an alkaline
phosphatase conjugate and Fast Red substrate, and counterstained with
hematoxylin. Fast Red can be viewed using both light and fluorescence
microscopy. The top panel (A) depicts infected cells viewed under light
microscopy, while the bottom panel (B) depicts cells from a different field
of the same coverslip viewed under fluorescence microscopy using a Texas
Red filter.
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during the course of these studies (Fig. 7). Immunosuppres-
sion was initiated 3 weeks prior to inoculation and was
maintained until week 30 (12033) or at least 4 weeks after
viral clearance. Immunosuppression was induced by twice
daily, oral administration of FK506 at 100 g/kg. The most
successful attempt at inducing persistent infection was with
12033. The animal was maintained on FK506 for 30 weeks
without any apparent adverse effects. At the time that treat-
ment was discontinued, the animal still exhibited a viremia
of greater than 108 GE/ml. The animal seroconverted for
antibody to NS3 on week 32 and had a minor ALT flare on
week 38 that resolved. The animal continued to have a
stable high-level viremia; however, RNA levels began to
decline on week 46. The animal spontaneously cleared on
week 48, 18 weeks after discontinuation of FK506. The
anti-NS3 antibody began to decline immediately upon viral
clearance. As in previous animals, the animal cleared vire-
mia in the absence of a rise in ALT, suggesting a noncyto-
pathic, cytokine-mediated viral clearance. The success of
immunosuppression was less apparent in the other three
tamarins. Two cleared viremia in 24 weeks (12034 and
16461) and one in 16 weeks (16460). The dose of FK506
was doubled at week 18 for both 16460 and 16461, but this
may have been too late to have an effect on the outcome of
the infection. Animal 16461 had an antibody response to
NS3 at week 20, prior to a decline in viremia, and while still
on FK506 therapy. No anti-NS3 response was observed in
12034 or 16460. Although no rise in ALT was noted in
16461, both 12034 and 16460 had elevations in ALT (73
and 112 IU/ml, respectively), and the peak in ALT occurred
prior to a decline in viremia. Although initially disappoint-
ing that persistent infections were not obtained with tran-
sient immunosuppression, the data (especially with 12033)
are encouraging that altered immunosuppressive regimes
may be more effective at least in providing animals with
stable, extended viremia. Similar to cyclosporin, FK506 is a
calcineurin inhibitor and is commonly used to prevent re-
jection of liver transplants and may be used in combination
with other immunosuppressive and antiproliferative drugs
(Moser, 2002). Combination therapy decreases organ rejec-
tion at lower drug levels, and thus decreases adverse effects,
and may be beneficial in the induction of persistent infection
in GBV-B-infected tamarins and marmosets. Alternatively,
animals can be inoculated at birth in an attempt to obtain
persistently infected animals. The value of having a colony
of persistently infected animals for future studies indicates
that additional efforts are warranted.
Materials and methods
Animals
Moustached tamarins (S. mystax), cotton top tamarins (S.
oedipus), common marmosets (C. jaccus), and black-
handed spider monkeys (Ateles paniscus) were housed at
the Southwest National Primate Research Center at the
Southwest Foundation for Biomedical Research. Animals
were cared for by members of the Department of Laboratory
Animal Medicine in accordance with the Guide for the Care
and Use of Laboratory Animals and all protocols were
approved by the Institutional Animal Care and Use Com-
mittee. FK506 (tacrolimus or Prograf) was purchased from
Fujisawa Pharmaceutical Co. The animals were provided
oral FK506 twice daily at 100 g/kg. The blood trough
levels were measured several times to ensure that therapeu-
tic levels were being obtained.
Hepatocyte cultures
Primary marmoset hepatocytes were isolated by collage-
nase perfusion as previously described (Beames et al., 2000;
Lanford and Estlack, 1998). Cells were frozen in liquid
nitrogen at the time of isolation and were revived and plated
on collagen-coated culture dishes as needed. Cultures were
maintained in a modification of our originally described,
hormonally defined, serum-free medium (Lanford and Est-
lack, 1998). The simplified, serum-free medium was com-
posed of Williams medium E supplemented with 10 mM
HEPES, pH 7.4, 2 mM glutamine, 500 g/ml bovine serum
albumin loaded with 5 g/ml linoleic acid, 100 ng/ml epi-
dermal growth factor, 10 g/ml insulin, 5 g/ml transferrin,
5 ng/ml selinum, 1 M dexamethasone, 1 M ethanol-
amine, and 50 g/ml gentamicin sulfate. Cells were grown
in six-well dishes for 3 days prior to infection. Inoculations
were performed with 5 l of GBV-B containing serum
(approximately 2  105 to 4  106 GE) in 1 ml of serum-
free medium for 6 h at 37°C followed by two washes to
remove residual inoculum. Culture medium was changed
three times per week. Hepatocytes grown on glass cover-
slips were harvested at 3 days postinfection and used for
immunohistochemical staining. Coverslips were fixed for
10 min in acetone and were stained with rabbit antiserum
directed against bacterial-expressed GST-NS3 protein. Im-
munohistochemistry was performed using the DAKO En-
vision System for alkaline phosphatase with Fast Red sub-
strate as described by the manufacturer.
TaqMan quantification of GBV-B RNA
GBV-B RNA was isolated from cells or medium by
extraction with RNazol (Biotecx Laboratories, Leedo, TX),
and total cell RNA was quantified by optical density.
GBV-B RNA was quantified by a real time, 5 exonuclease
RT-PCR (TaqMan) assay using a primer/probe combination
that recognized a portion of the GBV-B capsid gene as
previously described (Beames et al., 2000). The primers
(558F: 5AACGAGCAAAGCGCAAAGTC and 626R:
5CATCATGGATACCAGCAATTTTGT) and probe (579P:
56FAM-AGCGCGATGCTCGGCCTCGTA-TAMRA)
were selected using the Primer Express software designed
for this purpose and were purchased from PE Biosystems
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Fig. 7. Effect of immunosuppression on duration of viremia in GBV-B-infected tamarins. Tamarins were immunosuppressed by twice daily oral
administration of 100 g/kg FK506. Animals were inoculated with GBV-B 3 weeks after initiation of FK506 therapy, and FK506 was discontinued 30 weeks
postinoculation (12033) or after two consecutive RT-PCR-negative time points (4 weeks). The blood trough levels of FK506 were measured at multiple times
and found to be within the recommended therapeutic range for liver transplantation. The dose of FK506 was doubled at week 18 for 16460 and 16461.
Quantitative real-time RT-PCR (TaqMan) assays were used to determine the levels of GBV-B RNA in the serum, and values were expressed in genome
equivalents (GE)/ml of serum (shaded bars). Serum samples that were tested but were RT-PCR negative are indicated by shaded triangles. Liver damage,
as measured by serum ALT levels (open circles), and seroconversion for antibody to the NS3 protein (Anti- NS3 ELISA absorbance, triangles) are indicated
by line graphs.
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(Foster City, CA). Standards to establish genome equiva-
lents were synthetic RNAs transcribed from the cloned
GBV-B capsid gene.
Anti-NS3 ELISA
Antibodies to NS3 in GBV-B-infected animals were
monitored with ELISA using purified NS3 (Beames et al.,
2000). Purified NS3 protein (10 ng per well) was bound to
Immunlon 2, 96-well plates (Dynatech Laboratories, VA) in
borate-buffered saline (145 mM NaCl, 6 mM NaOH, 48
mM H3BO3, 50 mM KCI pH to 8.2) overnight at 4°C. All
ELISA incubations were for 1 h at 37°C, and wells were
washed four times with PBS-0.05% Tween 20 between
incubation steps. Unoccupied protein-binding sites were
blocked with 5% bovine serum albumin (BSA) in PBS.
Serial tamarin serum samples were diluted 1:40 in antibody
diluent, 0.5% BSA–PBS–0.05% Tween 20. Bound antibody
was detected with goat anti-human IgG horseradish perox-
idase conjugate diluted 1:1000 in antibody diluent. The
substrate (100 l of 1 mg/ml ABTS (Sigma) in 0.03%
H2O2) was incubated at room temperature until color de-
velopment was stopped by the addition of 50 l of 1% SDS.
Plates were read at 405 nm.
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